We evaluated the impact of clinical and molecular characteristics on overall survival (OS) in 108 patients with indolent (n = 41) and advanced systemic mastocytosis (SM) (advSM, n = 67). Organomegaly was measured by magnetic resonance imaging-based volumetry of the liver and spleen. In multivariate analysis of all patients, an increased spleen volume ⩾ 450 ml (hazard ratio (HR), 5.2; 95% confidence interval (CI), (2.1-13.0); P = 0.003) and an elevated alkaline phosphatase (AP; HR 5.0 (1.1-22.2); P = 0.02) were associated with adverse OS. The 3-year OS was 100, 77, and 39%, respectively (P o 0.0001), for patients with 0 (low risk, n = 37), 1 (intermediate risk, n = 32) or 2 (high risk, n = 39) parameters. For advSM patients with fully available clinical and molecular data (n = 60), univariate analysis identified splenomegaly ⩾ 1200 ml, elevated AP and mutations in the SRSF2/ASXL1/RUNX1 (S/A/R) gene panel as significant prognostic markers. In multivariate analysis, mutations in S/A/R (HR 3.2 (1.1-9.6); P = 0.01) and elevated AP (HR 2.6 (1.0-7.1); P = 0.03) remained predictive adverse prognostic markers for OS. The 3-year OS was 76 and 38%, respectively (P = 0.0003), for patients with 0-1 (intermediate risk, n = 28) or 2 (high risk, n = 32) parameters. We conclude that splenomegaly, elevated AP and mutations in the S/A/R gene panel are independent of the World Health Organization classification and provide the most relevant prognostic information in SM patients.
INTRODUCTION
Systemic mastocytosis (SM) comprises a group of rare myeloid neoplasms characterized by accumulation of mast cells (MC) in various tissues, predominantly bone marrow (BM), skin and visceral organs. Depending on the involvement of other hematopoietic lineages and disease-related organ damage, SM can be categorized into indolent SM (ISM) and advanced SM (advSM). AdvSM includes patients with SM and associated clonal hematological non-mast cell lineage disease (SM-AHNMD), aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). [1] [2] [3] [4] In contrast to ISM, advSM has a poor prognosis with median survival between few months in patients with MCL and o2-4 years in patients with SM-AHNMD and ASM. 5 Activating mutations in the receptor tyrosine kinase KIT, usually KIT D816V, are pathogenetically relevant somatic point mutations, detected in 480-90% of patients with SM. 6, 7 The multi-lineage expansion by KIT D816V and the KIT D816V allele burden (AB) have an important impact on disease phenotype and prognosis. 6, [8] [9] [10] Furthermore, the presence and the number of molecular aberrations, for example, in SRSF2, ASXL1 or RUNX1 (S/A/R gene panel), have a strong adverse impact on disease phenotype and overall survival (OS) in patients with advSM. 9, 11 One of the several World Health Organization (WHO) criteria to classify SM includes enlargement of visceral organs, for example, spleen, liver or lymph nodes. In addition to high MC burden in the BM, elevated serum tryptase 4200 μg/l and signs of dysplasia or myeloproliferation in the BM, organomegaly is an accepted B-finding that supports the diagnosis of smoldering SM. Signs of organ damage (C-findings), for example, cytopenia(s), hepatomegaly with impaired liver function, palpable splenomegaly with signs of hypersplenism, malabsorption with significant hypoalbuminemia and/or significant weight loss, support the diagnosis of advSM. However, only little is yet known about the prognostic impact of clinical and hematological characteristics, such as B-and C-findings.
We therefore sought to evaluate the impact of hepatomegaly and splenomegaly as objectively measured by magnetic resonance imaging (MRI)-based volumetry, as well as other known clinical and morphological characteristics, on prognosis in SM.
PATIENTS AND METHODS

Diagnosis and classification of SM
The diagnosis of SM was established according to the WHO classification: ISM (n = 41) and advSM (n = 67; ASM, n = 5; SM-AHNMD, n = 46; MCL, n = 7; MCL-AHNMD, n = 9). 1, 5, 12 Fifty-five patients had an AHNMD, including chronic myelomonocytic leukemia (n = 19), myelodysplastic/myeloproliferative neoplasm unclassified (n = 19), chronic eosinophilic leukemia (n = 9), acute myeloid leukemia (n = 5) and myelofibrosis (MF, n = 3). BM biopsies were evaluated by reference pathologists of the European Competence Network on Mastocytosis (H-PH and KS). Cytoreductive treatment in 61/67 patients with advSM included midostaurin (n = 14), cladribine (n = 5), cladribine following midostaurin or vice versa (n = 16), midostaurin (n = 6) or cladribine (n = 2) followed by intensive chemotherapy with (n = 2) or without (n = 6) allogeneic stem cell transplantation. Ten patients were treated with hydroxyurea (n = 6), nilotinib (n = 2) or decitabine (n = 2).
The diagnosis of ASM was based on the presence of one or more C-findings (cytopenia with an absolute neutrophil count o1 × 10 9 /l, hemoglobin o10.0 g/dl, platelets o100 × 10 9 /l, hepatomegaly with impaired liver function, palpable splenomegaly with signs of hypersplenism, malabsorption with significant hypoalbuminemia and/or significant weight loss 410% over the past 6 months).
2,5,13 Diagnosis of MCL was based on the presence of at least 20% MC in BM smears with or without C-findings. The diagnosis AHNMD was established by evaluating peripheral blood (for example, monocytosis and/or eosinophilia) and BM by morphology, histology and immunohistochemistry using WHO criteria and a panel of standard markers, depending on the suspected AHNMD subtype.
In all patients with significant eosinophilia (41 × 10 9 /l), the presence of FIP1L1-PDGFRA or other rearrangements of PDGFRA, PDGFRB or FGFR1 were excluded by cytogenetics (no rearrangement of 4q12, 5q31-33 or 8p11), RT-PCR (no fusion gene) and/or fluorescence in situ hybridization analysis (no rearrangement). The study design adhered to the tenets of the Declaration of Helsinki and was approved by the institutional review board of the Medical Faculty of Mannheim, University of Heidelberg, as part of the 'German Registry on Disorders of Eosinophils and Mast Cells'. All patients gave written informed consent.
Gene mutation analyses
Analysis for mutations in KIT and quantitative assessment of the KIT D816V expressed AB (EAB) were performed by allele-specific quantitative real-time polymerase chain reaction as described. 6 Next-generation deep Table 1 . Clinical, laboratory and magnetic resonance imaging (MRI)-derived volumetric analysis and findings of 108 patients with systemic mastocytosis, stratified by spleen volume o 450 ml (no splenomegaly), ⩾ 450 ml ando 1200 ml (mild splenomegaly) or ⩾ 1200 ml (marked splenomegaly)
Variables
All patients (n = 108)
Spleen volume o450 ml (n = 41)
Spleen volume
⩾ 450 and o1200 ml (n = 43)
Spleen volume ⩾ 1200 ml (n = 24) P, a spleen volume o450 ml vs ⩾ 450 ml P, a spleen volume ⩾ 450 and o1200 ml vs ⩾ 1200 ml P-values refer to log-rank tests comparing patients with spleen volume o450 and ⩾ 450 ml or ⩾ 450, o 1200 and ⩾ 1200 ml.
amplicon sequencing by 454 FLX amplicon chemistry (Roche, Penzberg, Germany) was performed to investigate 18 genes recurrently mutated in myeloid neoplasms as previously described. 9 
MRI-based volumetry
All examinations were performed on a 1.5 T whole-body MRI system (Magnetom Avanto, Siemens Healthcare, Erlangen, Germany). Volume measurements of the liver and spleen were performed by a resident (JC) using a FDA-approved, commercially available software (Aycan OsiriX pro v.2.06 64 Bit, Rochester, NY, USA). Results were verified by a board-certified radiologist (DH). For volume measurements, gadolinium-based, contrastenhanced, axial T1-weighted sequences were utilized that covered both organs (T1 vibe fs tra; acquisition matrix 384 × 225; slice thickness 3 mm; FoV 296 × 379 mm 2 ). Regions of interest were drawn surrounding the surface of each organ in all slices. Subsequently, volume calculation was performed automatically by the software by interpolating and summing up the planimetric results to a single volume. The abdominal MRI also allowed identification and measurement of ascites and abdominal lymphadenopathy.
Statistical analyses
All statistical analyses considered clinical and laboratory parameters obtained at the time of MRI. OS analysis was considered from the date of MRI to the date of death or last contact. Pearson's correlation analysis was performed for the correlation between two parameters, for example, there was a positive correlation if both parameters had a tendency to increased levels and a negative correlation if one parameter had the tendency to increase, the other to decrease. Differences in the distribution of continuous variables between categories were analyzed by either Mann-Whitney test (for comparison of two groups) or Kruskal-Wallis test (for comparison of three groups). For categorical variables, Fishers's exact test was used. For univariate (including almost all SM-related parameters) and multivariate analyses, receiver operating characteristic curve with a time-dependent survival probability were used to identify optimal cut-off points. OS probabilities were estimated with the Kaplan-Meier method and compared by log-rank test in univariate analysis. For the estimation of hazard ratios (HRs) and multivariate analysis, the Cox proportional hazard regression model was used (backward selection). P-valueso0.05 (two sided) were considered significant. There was no adjustment for multiple testing as all analyses were explorative. SPSS version 22.0.0 (IBM Corporation, Armonk, NY, USA) and SAS version 9.2 (SAS Institute, Cary, NC, USA) were used for statistical analysis.
RESULTS
Patients
The study group included 108 patients with a median age of 64 years (range 27-82). Relevant SM-associated disease characteristics are presented in Table 1 . The median BM MC infiltration, determined by BM immunohistochemistry, was 20% (range 5-95), and the median serum tryptase was 127 μg/l (range 13-951, normal value o11.4). Ninety-eight percent (106/108) of the patients were KIT D816V positive, one patient was KIT D816H positive, and one patient was negative for KIT mutations. The median KIT D816V EAB in peripheral blood (available in 101/108 patients) was 22% (range 1-99).
Median blood counts were as follows: leukocytes 8.0 × 10 9 /l, hemoglobin 12.3 g/dl ( o10 g/dl in 22% of patients), platelets 181 × 10 9 /l (o 100 × 10 9 /l in 25% of patients), monocytes 0.5 × 10 9 /l (41 × 10 9 /l in 21% of patients), and eosinophils 0.2 × 10 9 /l (41 × 10 9 /l in 19% of patients). Non-hematological C-findings included hypoalbuminemia ( o35 g/l) in 26% of patients, and elevated alkaline phosphatase (AP, 4150 U/l in 41% of patients; normal value 40-150). Median observation time Figure 1 . The heat map displays correlations between two individual parameters. Colors were assigned on basis of the value of the *Pearson's correlation coefficient (r). For example, a strong positive correlation (the other variable has a tendency to increase, in blue) was observed between spleen volume and liver volume or liver volume and ascites while a strong negative correlation (the other variable has a tendency to decrease, in red) was observed between spleen volume and platelets/hemoglobin or between ascites and albumin. Hb, hemoglobin; LNA, lymphadenopathy; MC, mast cell infiltration; MLE, multi-lineage expansion; PLT, platelets. **All correlations are statistically significant with the exception of the correlation between LNA and tryptase.
Spleen volume, alkaline phosphatse and mutations in SM M Jawhar et al from the date of MRI was 26 months (range 1-79); 36/108 patients (33%) died in the observation period. The 3-year OS probability of all patients was 64%, with a median OS of 5.4 years.
MRI findings
In advSM, MRI was performed within 6 months of primary diagnosis in 82% of patients and, in the remaining patients, within 12 months of diagnosis. The median volumes of the liver and spleen were 2035 ml (range 1034-4265) and 540 ml (range 92-3193), respectively. Receiver operating characteristic analysis identified a spleen volume of 450 ml as optimal volumetric thresholds for all patients and 1200 ml for patients with advSM only. The optimal cutoff for hepatomegaly was 2400 ml for all patients.
Overall, MRI-documented hepatomegaly was observed in 31/108 patients (29%) and splenomegaly in 67/108 patients (62%). Splenomegaly was mild (⩾ 450 and o 1200 ml) in 43/67 patients (64%) and marked (⩾ 1200 ml) in 24/67 patients (36%). Ascites and lymphadenopathy were detected in 37/108 patients (34%) and 52/108 patients (48%), respectively ( Table 1 ). Pearson's analyses showed a strong positive correlation between spleen and liver volume or liver volume and ascites. A strong negative correlation was observed between spleen volume and platelets/hemoglobin or ascites and albumin. Other correlations are shown in Figure 1 .
Correlation between spleen volume and clinical phenotype In ISM (n = 41, 38% of all patients), splenomegaly was observed in 8/41 patients (20%). In contrast, splenomegaly (mild or marked) was present in 59/67 (88%) patients with advSM. The comparison between no splenomegaly and any type of splenomegaly (mild or marked) revealed significant differences in almost all parameters, including age, B-findings, C-findings, BM MC infiltration, serum tryptase and KIT D816V EAB (Table 1) . When patients with mild and marked splenomegaly were compared, the median platelet count, elevated AP (4150 U/l), liver volume and ascites were significantly different, indicating a more aggressive phenotype in patients with marked splenomegaly (Table 1) .
Impact of spleen volume on OS The spleen volume was significantly associated with adverse OS. Pairwise significantly different OS probabilities were observed for the comparison between no splenomegaly (n = 41) vs any Figure 2 . (a) Kaplan-Meier estimates of OS of patients depending on the spleen volume and AP in 108 patients with SM: spleen volume o450 ml (n = 41, blue line) vs spleen volume ⩾ 450 and o1200 ml (n = 43, yellow line) vs spleen volume ⩾ 1200 ml (n = 24, red line); normal AP (⩽150 U/l, n = 64, blue line); and elevated AP (4150 U/l, n = 44, red line). (b) Kaplan-Meier estimates of OS of patients depending on the spleen volume and AP in 60 patients with advSM and known mutation profile in the S/A/R gene panel; spleen volume o1200 ml (n = 39, yellow line) vs spleen volume ⩾ 1200 ml (n = 21, red line); normal AP (⩽150 U/l, n = 22, blue line) vs elevated AP (4150 U/l, n = 38, red line). Significantly different OS probabilities were observed for the pairwise comparison. The P-values refer to log-rank tests and the HR (hazard ratio) is presented together with the 95% CI.
splenomegaly (n = 67, median not reached vs 3.1 years, HR 10.7 (2.6-44.7), P o 0.0001), no splenomegaly (n = 41) vs mild splenomegaly (n = 43, HR 6.9 (1.6-30.1), P = 0.003), no splenomegaly vs marked splenomegaly (n = 24, HR 33.9 (4.5-255.4), P o 0.0001) and mild splenomegaly vs marked splenomegaly (HR 2.6 (1.3-5.3), P = 0.005). The 3-year OS was 98, 68 and 30% for patients with no splenomegaly, mild splenomegaly and marked splenomegaly, respectively (Table 1, Figure 2a) .
Correlation between liver volume, clinical phenotype and OS Hepatomegaly was observed in 3/41 (7%) and 28/67 (42%) patients with ISM and advSM, respectively. The comparison between no hepatomegaly and hepatomegaly revealed significant differences regarding almost all parameters, including C-findings, BM MC infiltration, serum tryptase and KIT D816V EAB. Almost all patients (29/31, 94%) with hepatomegaly had any form of splenomegaly (mild or marked) but not vice versa. Univariate and multivariate analyses of SM-related parameters The results of univariate analyses for multiple clinical and laboratory variables concerning OS were significant as follows: age ⩾ 65 years (HR 4.1 (1.9-9.0), P = 0.0002), cytopenia (hemoglobin o 10 g/dl and/or platelets o 100 × 10 9 /l, HR 4.5 (2.2-9.2), P o0.0001), ascites (HR 3.2 (1.6-6.5), P = 0.004), elevated AP (4150 U/l, HR 8.3 (3.4-19.9), P o0.0001), hypoalbuminemia (HR 2.7 (1.4-5.2), P = 0.002), markedly elevated serum tryptase (4200 μg/l, HR 3.6 (1.7-7.3), P = 0.0002), hepatomegaly (42400 ml, HR 2.5 (1.3-4.9), P = 0.007), any splenomegaly (⩾ 450 ml, HR 10.7 (2.6-44.7), P o 0.0001), lymphadenopathy (HR 2.2 (1.1-4.6), P = 0.03), multi-lineage expansion (monocytes 41 × 10 9 /l and/or eosinophils 41 × 10 9 /l, HR 3.5 (1.8-6.7), P o0.0001), and KIT D816V EAB in peripheral blood 430% (HR 3.3 (1.7-6.5), P = 0.0003). In multivariate analyses including all clinical and hematological variables with significant prognostic value in univariate analyses, only splenomegaly ⩾ 450 ml (HR 5.2 (2.1-13.0), P = 0.003) and elevated AP (HR 5.0 (1.1-22.2), P = 0.02) remained independent poor risk factors for OS (Table 2a , Figure 2a ). Regarding the comparison of the disparate WHO subgroups, for example, ISM vs advSM, ASM vs MCL, ASM vs SM-AHNMD and MCL vs SM-AHNMD, only ISM vs advSM (P o 0.0001) was significant in univariate analysis but was not significant in multivariate analyses.
In univariate analyses of 60/67 patients with advSM and available mutation status of the S/A/R gene panel, marked splenomegaly (⩾1200 ml, HR 3.0 (1.4-6.4), P = 0.002), elevated AP (4150 U/l, HR 3.6 (1.6-9.3), P = 0.006) and mutations in the S/A/R gene panel (HR 4.3 (1.5-12.4), P = 0.003) were significant with regard to OS. In multivariate analysis, elevated AP (HR 2.6 (1.0-7.1), P = 0.03) and mutations in the S/A/R gene panel (HR 3.2 (1.1-9 .6), P = 0.01) remained independent poor risk factors for OS (Table 2b , Figure 2b ).
Risk stratification
The risk stratification was designed based on the two independent parameters identified in multivariate analysis, attributing points according to their rounded HR value (Table 2a) : 0 point (low risk, n = 37) for patients without splenomegaly and normal AP, 1 point (intermediate risk, n = 32) for patients with any splenomegaly or elevated AP, and 2 points (high risk, n = 39) (Figure 3a) for patients with any splenomegaly and elevated AP. Thus 39/67 (58%) patients with advSM were classified as high risk and 28/67 (42%) were classified as low/intermediate risk (Figure 4a ). The median number of C-findings was significantly higher in high risk patients. For the cases with available DNA for next-generation sequencing (74/108, 69%), there was a significantly higher incidence of mutations in the S/A/R gene panel in intermediate (12/24, 50%) and high risk (28/35, 80%) patients as compared with low risk patients (0/15) (P o0.0001). The 3-year OS probabilities of patients with low, intermediate and high risk were 100, 77 and 39%, respectively (P o0.0001, Table 3a, Figure 3a) .
In the subgroup of patients with advSM and available mutation status of the S/A/R gene panel, a prognostic model was established based on the multivariate analysis (Table 2b) risk (Figure 4b ). Furthermore, there was a significant correlation between massive splenomegaly and high risk patients because 17/21 (81%) patients with massive splenomegaly were classified as high risk (P = 0.003). The median OS probabilities of patients with high and intermediate risk were 24 months and not reached with a 3-year OS of 38% and 76%, respectively (P = 0.0003, Table 3b, Figure 3b ).
DISCUSSION
On the basis of univariate and multivariate analyses, we demonstrate that splenomegaly, elevated AP and mutations in the S/A/R gene panel are strong and independent adverse prognostic parameters for OS in patients with SM. Importantly, these factors are independent of the WHO classification and delineate new risk categories for patients with ISM and advSM.
Splenomegaly is one of the most prominent clinical characteristics in patients with myeloproliferative neoplasms and is included in widely applied prognostic scoring systems, for example, in chronic myeloid leukemia. [14] [15] [16] Splenomegaly is not included in established prognostic scoring systems for MF but data from ruxolitinib-based clinical trials have demonstrated an adverse prognostic impact of the initial spleen volume and the lack of spleen volume reduction on treatment. [17] [18] [19] In MF, these Spleen volume, alkaline phosphatse and mutations in SMassociations were only established because the spleen volume was accurately measured by volumetry through computed tomography or MRI. Splenomegaly and/or hepatomegaly and the related organ damage are also considered as clinically relevant parameters in patients with SM. Although splenomegaly is not part of the WHO diagnostic criteria, it is an important criterion for the classification of SM through B-and C-findings as well as identifying disease progression. However, the prognostic value of splenomegaly has not yet been thoroughly evaluated. Marked reduction of spleen volume as assessed by computed tomography/MRI has also been recently reported for patients with advSM on midostaurin (PKC412), rendering it a valid and reliable parameter for the assessment of response to treatment. Accordingly, an IWG-MRT (ELN (European LeukemiaNet) and ECNM (European Competence Network on Mastocytosis)) expert panel included spleen response in MF and SM in their response criteria. The panel recognized the highly subjective nature of the assessment of spleen and liver size by physical examination and therefore recommended objective confirmation by computed tomography/MRI. 20, 21 In comparison to splenomegaly, hepatomegaly was significantly less frequently observed in patients with advSM and only rarely in ISM. Of note, hepatomegaly was strongly associated with the presence of splenomegaly but not vice versa. Low albumin, increased liver enzymes and/or portal hypertension with splenomegaly and ascites characterize hepatomegaly with dysfunction of the liver. However, little is known about distinct differences between the various laboratory parameters, for example, albumin, aspartate aminotransferase, alanine transaminase, AP, gammaglutamyltransferase (GGT) and bilirubin. 22 In our patient cohort, aspartate aminotransferase, alanine transaminase and bilirubin were only elevated in a minority of patients while elevated AP and, to a lesser extent, also elevated GGT were identified in the vast majority of patients with advSM. In subsequent analyses, elevated AP had a significantly stronger impact on OS as compared with elevated GGT. Although the associated increase of AP and GGT already indicated the source of AP being hepatic but not osseous, AP isoenzyme analyses were performed in 25 patients proving the predominant hepatic origin in 24/25 patients. In addition, all nine patients with histologically confirmed MC infiltration had an elevated AP (data not shown).
We have recently shown the strong adverse impact of mutations in the S/A/R gene panel on OS in patients with advSM. 11 We therefore included mutation profiles in our analyses and delineated intermediate and high risk subgroups of advSM patients based on elevated AP and S/A/R mutations. An SM patient at the highest risk (median survival of 24 months) is characterized by the presence of an AHNMD, marked splenomegaly, elevated AP and mutations in the S/A/R gene panel. Of note, all these parameters are easily accessible and serial measurements may thus assist in determining responses to antineoplastic therapy. 23 Because patient numbers are limited, we are aware that parameters that were excluded in the current model may become more significant in larger series.
In conclusion, splenomegaly, elevated AP and mutations in the S/A/R gene panel provide highly relevant prognostic information for all subvariants of SM, independently of other clinical, hematological and laboratory parameters and also the WHO classification. Similar to other subtypes of myeloid neoplasms, it is likely that clinical and molecular markers complement each other and will have major implications on forthcoming prognostic scoring systems on the basis of larger patient cohorts, such as the dataset of the ECNM registry, with the long-term objective to develop an International Prognostic Scoring System for patients with SM.
